{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:08:09Z","timestamp":1751947689378,"version":"3.41.2"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T00:00:00Z","timestamp":1539475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Food and Drug Administration (FDA) has recently included a black box warning on fibromyalgia\u2010like symptoms with fluoroquinolones (FQs) but no large epidemiologic study is to date available. We undertook a case\u2013control study using a random sample of 9\u2009053\u2009240 subjects obtained from the PharMetrics Plus health claims database in the United States. Cases received at least two fibromyalgia diagnoses coded by a rheumatologist matched to ten randomly selected controls. After identifying 5148 cases of fibromyalgia and 51\u2009480 controls, the adjusted rate ratio (RR) of fibromyalgia for use of any fluoroquinolones, amoxicillin and azithromycin were 1.63 (95% CI: 1.41\u20131.87), 1.64 (95% CI: 1.46\u20131.85) and 1.68 (95% CI, 1.49\u20131.89), respectively. The adjusted RR for any use of FQ compared to any use of amoxicillin or azithromycin was 0.99 (95% CI: 0.83\u20131.18) and azithromycin is 0.97 (95%CI: 0.82\u20131.16), respectively. The risk of fibromyalgia with FQs is similar to that with amoxicillin and azithromycin.<\/jats:p>","DOI":"10.1111\/bcp.13765","type":"journal-article","created":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T07:30:29Z","timestamp":1537083029000},"page":"236-239","source":"Crossref","is-referenced-by-count":6,"title":["Oral fluoroquinolones and risk of fibromyalgia"],"prefix":"10.1111","volume":"85","author":[{"given":"Saeed","family":"Ganjizadeh\u2010Zavareh","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medicine University of British Columbia Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Sodhi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine University of British Columbia Vancouver Canada"},{"name":"Department of Ophthalmology and Visual Sciences and Pharmacology University of British Columbia Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tori","family":"Spangehl","sequence":"additional","affiliation":[{"name":"MD Undergraduate Program, Faculty of Medicine University of British Columbia Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-4054","authenticated-orcid":false,"given":"Bruce","family":"Carleton","sequence":"additional","affiliation":[{"name":"Division of Translational Therapeutics, Department of Pediatrics University of British Columbia Vancouver Canada"},{"name":"British Columbia Children's Hospital Research Institute University of British Columbia Vancouver Canada"},{"name":"Pharmaceutical Outcomes Program British Columbia Children's Hospital Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4628-6270","authenticated-orcid":false,"given":"Mahyar","family":"Etminan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences and Pharmacology University of British Columbia Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,10,14]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"FDA updates warnings for fluoroquinolone antibiotics[online]. Available athttps:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm513183.htm(last accessed 5 October 2018)."},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-209821","article-title":"Fluoroquinolone\u2010induced serious, persistent, multisymptom adverse effects","volume":"2015","author":"Golomb BA","year":"2015","journal-title":"BMJ Case Rep"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2003.10.016"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000846"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix362"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/PHM.0000000000000300"},{"key":"e_1_2_9_8_1","unstructured":"Quintiles IMS real\u2010world data adjudicated claims: USA [QuintilesIMS PharMetrics Plus][online]. Available athttps:\/\/www.bridgetodata.org\/node\/824(last accessed 5 October 2018)."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00512-X"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1046975"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0026-895X(25)09546-X","article-title":"Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin\u2010treated mammalian cells","volume":"50","author":"Lawrence JW","year":"1996","journal-title":"Mol Pharmacol"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25628"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-003-0032-2"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780301007"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i20.6024"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i7.2219"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0294-z"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.4161\/gmic.1.4.12613"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400311"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13765","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13765","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13765","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:48:03Z","timestamp":1751888883000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,14]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/bcp.13765"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13765","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2018,10,14]]}}}